Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization -14% primary Improvement Relative Risk c19ivm.org Szente Fonseca et al. Ivermectin for COVID-19 EARLY Is early treatment with ivermectin beneficial for COVID-19? Retrospective 717 patients in Brazil No significant difference in hospitalization Szente Fonseca et al., Travel Medicine and Infec.., doi:10.1016/j.tmaid.2020.101906 Favors ivermectin Favors control
Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens in Brazil: Comparative Analysis
Szente Fonseca et al., Travel Medicine and Infectious Disease, doi:10.1016/j.tmaid.2020.101906
Szente Fonseca et al., Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens in Brazil: Comparative.., Travel Medicine and Infectious Disease, doi:10.1016/j.tmaid.2020.101906
Oct 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 717 patients in Brazil showing OR 1.17 [0.72-1.90] for ivermectin. This paper focuses on HCQ, event counts for ivermectin are not provided. With significant correlation between the variables used, including overlap in the prescription of multiple treatments that show efficacy alone, and limited data for the model size, the model used here may be inaccurate due to multicollinearity [statisticsbyjim.com]. This study is excluded in the after exclusion results of meta analysis: result is likely affected by collinearity across treatments in the model.
risk of hospitalization, 13.9% higher, RR 1.14, p = 0.53, treatment 340, control 377, adjusted per study, odds ratio converted to relative risk, control prevalence approximated with overall prevalence, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Szente Fonseca et al., 31 Oct 2020, retrospective, Brazil, peer-reviewed, mean age 50.6, 10 authors, average treatment delay 4.6 days, dosage 12mg days 1-2.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Journal Pre-proof Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens in Brazil: Comparative Analysis Silvia Nunes Szente Fonseca, Anastasio Queiroz de Sousa, Alexandre Giandoni Wolkoff, Marcelo Sampaio Moreira, Bruno Castro Pinto, Christianne Fernandes Valente Takeda, Eduardo Rebouças, Ana Paula Vasconcellos Abdon, Anderson L.A. Nascimento, Harvey A. Risch PII: S1477-8939(20)30402-6 DOI: https://doi.org/10.1016/j.tmaid.2020.101906 Reference: TMAID 101906 To appear in: Travel Medicine and Infectious Disease Received Date: 14 August 2020 Revised Date: 10 September 2020 Accepted Date: 26 October 2020 Please cite this article as: Szente Fonseca SN, Queiroz de Sousa A, Wolkoff AG, Moreira MS, Pinto BC, Valente Takeda CF, Rebouças E, Vasconcellos Abdon AP, Nascimento ALA, Risch HA, Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens in Brazil: Comparative Analysis, Travel Medicine and Infectious Disease, https://doi.org/10.1016/j.tmaid.2020.101906. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Published by Elsevier Ltd. Silvia Nunes Szente Fonseca: Conceptualization, Investigation, Resources, Data Curation, Writing Original Draft, Project administration Anastasio Queiroz de Sousa: Investigation, Resources, Data Curation, Writing - Review & Editing Alexandre Giandoni Wolkoff: Conceptualization, Investigation, Resources, Data Curation, Writing Review & Editing, Project administration Marcelo Sampaio Moreira: Investigation, Resources, Data Curation, Writing - Review & Editing Bruno Castro Pinto: Investigation, Resources, Data Curation, Writing - Review & Editing of Christianne Fernandes Valente Takeda: Investigation, Resources, Data Curation, Writing - Review & Editing Eduardo Rebouças: Investigation, Resources, Data Curation, Writing - Review & Editing ro Ana Paula Vasconcellos Abdon: Investigation, Resources, Data Curation, Writing - Review & Editing -p Anderson L. A. Nascimento: Investigation, Resources, Data Curation, Writing - Review & Editing Jo ur na lP re Harvey A. Risch: Conceptualization, Investigation, Data Curation, Formal Analysis, Writing - Review & Editing 1 Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens in Brazil: Comparative Analysis Silvia Nunes Szente Fonseca 1, Anastasio Queiroz de Sousa 2, Alexandre Giandoni Wolkoff 3, Marcelo Sampaio Moreira 3, Bruno Castro Pinto 3, Christianne Fernandes Valente Takeda 3, Eduardo Rebouças 3, Ana Paula Vasconcellos Abdon 4, Anderson L. A. Nascimento 3, Harvey A. Risch 5, 6 Hospital São Francisco, Ribeirão Preto, Brazil 2 Federal University of Ceará, Ceará , Brazil 3 Hapvida Saúde HMO, Fortaleza, Brazil 4 University of Fortaleza, Fortaleza, Brazil 5 Yale School of Public Health, New Haven, Connecticut USA 6 Correspondence to: Harvey A. Risch, M.D., Ph.D., Yale School of Public Health, 60 lP re -p ro of 1 na College St., PO..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit